Liu Bo, Ren Kang-Kang, Wang Nian, Xu Xin-Ping, Wu Jue
Department of Laboratory, Hospital No. 967 of PLA, Dalian 116000, Liaoning Province, China.
Gaoxin Hospital, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
World J Clin Cases. 2021 Apr 26;9(12):2890-2898. doi: 10.12998/wjcc.v9.i12.2890.
Convalescent plasma therapy is used for the treatment of critically ill patients for newly discovered infectious diseases, such as coronavirus disease 2019 (COVID-19) pneumonia, under the premise of lacking specific treatment drugs and corresponding vaccines. But the best timing application of plasma therapy and whether it is effective by antiviral and antibiotic treatment remain unclear.
We describe a patient with COVID-19, a 100-year-old, high-risk, elderly male who had multiple underlying diseases such as stage 2 hypertension (very high-risk group) and infectious pneumonia accompanied by chronic obstructive pulmonary disease and emphysema. We mainly describe the diagnosis, clinical process, and treatment of the patient, including the processes of two plasma transfusion treatments.
This provides a reference for choosing the best timing of convalescent plasma treatment and highlights the effectiveness of the clinical strategy of plasma treatment in the recovery period of patients with COVID-19 pneumonia.
在缺乏特异性治疗药物和相应疫苗的前提下,恢复期血浆疗法被用于治疗新型传染病的重症患者,如2019冠状病毒病(COVID-19)肺炎。但血浆疗法的最佳应用时机以及抗病毒和抗生素治疗是否有效仍不明确。
我们描述了一名患有COVID-19的患者,一名100岁的高危老年男性,患有多种基础疾病,如2级高血压(极高危组)以及伴有慢性阻塞性肺疾病和肺气肿的感染性肺炎。我们主要描述了该患者的诊断、临床过程和治疗情况,包括两次血浆输注治疗的过程。
这为选择恢复期血浆治疗的最佳时机提供了参考,并突出了血浆治疗临床策略在COVID-19肺炎患者恢复期的有效性。